Peptide profile
TB-500
Thymosin beta-4 fragment for wound repair · also known as Thymosin Beta-4 fragment, Tβ4 fragment
Compare TB-500 with other peptides →Summary
A synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in actin regulation, tissue repair, and inflammation modulation.
- Typical dose
- 2.0-2.5 mg twice weekly
- Half-life
- Estimated 30-120 minutes (active fraction)
- Route
- Subcutaneous, Intramuscular
- Cycle length
- 4-6 weeks loading, then 2 mg/month maintenance
Mechanism
How it works
Binds to actin and promotes cell migration, angiogenesis, and upregulation of repair-related growth factors including IGF-1 and HGF.
Reported in research
Benefits
- Accelerated healing of tendons, ligaments, and muscle
- Reduced inflammation in injured tissue
- Improved flexibility and reduced tissue adhesions
- Potential cardiac tissue protection
Context, not a prescription
Dosing
- Typical range
- 2.0-2.5 mg twice weekly (Subcutaneous, Intramuscular)
- Cycle length
- 4-6 weeks loading, then 2 mg/month maintenance
- Half-life
- Estimated 30-120 minutes (active fraction)
Safety
Side effects & contraindications
Possible side effects
- Injection-site discomfort
- Temporary fatigue or lethargy (reported informally)
- Headache (rare)
Contraindications
- Active malignancy (theoretical, due to angiogenesis and cell migration)
- Pregnancy (insufficient safety data)
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Less swelling, faster wound healing, and smaller scars.
How it works
Think of TB-500 like a road crew. It clears the streets, guides traffic, and builds new roads so healing supplies can reach where they're needed.
It helps special cells move and turn into new blood tubes.
What to expect
Less swelling in 1-2 weeks. Wounds close up by 4-6 weeks.
- Weeks 1-2: Less swelling and less pain.
- Weeks 3-4: Wounds close up faster.
- Weeks 4-6: The biggest healing benefits show up.
Good to know
- Start with a smaller dose (2mg)
- Space out your shots evenly
- Keep everything clean and germ-free
Staying safe
- Sore spot where you got the shot
- Feeling a little tired
- Headache
Avoid if you have:
- People with active cancer
- Women who are pregnant or breastfeeding
- People whose cells grow in unusual ways
Mechanism of action
TB-500 binds to actin, supports migration of repair cells to injured tissue, and encourages blood vessel growth.
Promotes endothelial cell migration and differentiation into new blood vessels.
Pharmacodynamics
Inflammation reduction within 1-2 weeks; wound closure by 4-6 weeks.
Reduced inflammation, accelerated wound healing, reduced scar formation.
Timeline
- Weeks 1-2: Reduced inflammation and pain.
- Weeks 3-4: Accelerated wound closure.
- Weeks 4-6: Maximum regenerative benefits.
Comparisons
- TB-500 — effectiveness Moderate, safety Good, cost $$, Medium to use
- BPC-157 — effectiveness High, safety Good, cost $$, Medium to use
Adverse effects
Common:
- Injection site pain
- Mild fatigue
- Headache
Rare:
- Nausea
- Flushing
- Dizziness
Contraindications & risk mitigation
Contraindicated in:
- Active cancer
- Pregnancy or breastfeeding
- Those with abnormal cell growth
- Start with lower dose (2mg)
- Space injections evenly
- Use sterile technique
Qué hace
Menos hinchazón, cicatrización más rápida de heridas y cicatrices más pequeñas.
Cómo funciona
Piensa en TB-500 como una cuadrilla de obras. Limpia las calles, dirige el tráfico y construye nuevas vías para que los suministros de curación lleguen donde se necesitan.
Ayuda a que células especiales se muevan y se conviertan en nuevos vasos sanguíneos.
Qué esperar
Menos hinchazón en 1-2 semanas. Las heridas se cierran en 4-6 semanas.
- Semanas 1-2: Menos hinchazón y menos dolor.
- Semanas 3-4: Las heridas se cierran más rápido.
- Semanas 4-6: Aparecen los mayores beneficios de curación.
Bueno saber
- Comenzar con una dosis más pequeña (2 mg)
- Espaciar las inyecciones por igual
- Mantener todo limpio y libre de gérmenes
Manteniéndose seguro
- Dolor en el lugar de la inyección
- Sentirse un poco cansado
- Dolor de cabeza
Evitar si tienes:
- Personas con cáncer activo
- Mujeres embarazadas o en lactancia
- Personas con crecimiento celular inusual
Mecanismo de acción
TB-500 se une a la actina, apoya la migración de células reparadoras hacia el tejido lesionado y fomenta el crecimiento de vasos sanguíneos.
Promueve la migración y diferenciación de células endoteliales en nuevos vasos sanguíneos.
Farmacodinamia
Reducción de la inflamación en 1-2 semanas; cierre de heridas en 4-6 semanas.
Reducción de la inflamación, cicatrización acelerada de heridas y menor formación de cicatrices.
Cronología
- Semanas 1-2: Reducción de la inflamación y el dolor.
- Semanas 3-4: Cierre acelerado de heridas.
- Semanas 4-6: Beneficios regenerativos máximos.
Comparaciones
- TB-500 — efectividad Moderada, seguridad Buena, costo $$, Media de usar
- BPC-157 — efectividad Alta, seguridad Buena, costo $$, Media de usar
Efectos adversos
Comunes:
- Dolor en el sitio de inyección
- Fatiga leve
- Dolor de cabeza
Raros:
- Náuseas
- Enrojecimiento
- Mareos
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Cáncer activo
- Embarazo o lactancia
- Personas con crecimiento celular anormal
- Comenzar con dosis más baja (2 mg)
- Espaciar las inyecciones uniformemente
- Usar técnica estéril
Reference data
Specifications
- Molecular formula
- C212H350N56O78S
- Molecular weight
- 4963.5 g/mol
- Half-life
- Estimated 30-120 minutes (active fraction)
- Route
- Subcutaneous, Intramuscular
- Cycle length
- 4-6 weeks loading, then 2 mg/month maintenance
- Storage
- Lyophilized: stable at room temperature for several weeks. Reconstituted: refrigerate at 2-8 C, use within 30 days.
- Legal status
- Research chemical; not approved for human therapeutic use in major regulatory jurisdictions.
FAQ
Common questions
Can TB-500 be stacked with BPC-157?
Yes, they are commonly stacked for synergistic wound healing and tissue repair.
Is TB-500 effective for skin wounds?
Yes, animal studies show accelerated wound closure and reduced scar formation.
What is the evidence level?
This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Research
Research & sources
Current evidence for TB-500 is rated as Animal data. Research is based primarily on animal models.
- 1. Thymosin beta-4 and wound healing (2007) — DOI:10.1111/j.1749-6632.2007.tb00465.x
- 2. TB-500 in tissue regeneration (2005) — DOI:10.1586/17434440.2.6.729
- 3. Goldstein et al. — Thymosin Beta-4 and tissue repair
- 4. Sosne et al. — Thymosin Beta-4 anti-inflammatory effects
Explore